ACM
AVBP icon

Aster Capital Management’s ArriVent BioPharma AVBP Stock Holding History

Aster Capital Management’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-73
Closed -$1.47K – 1398
2025
Q4 		$1.47K Buy
+73
New +$1.52K ﹤0.01% 985
2025
Q3 		– Sell
-8,730
Closed -$190K – 1430
2025
Q2 		$190K Buy
8,730
+8,449
+3,007% +$175K 0.04% 388
2025
Q1 		$6.63K Sell
281
-274
-49% -$6.71K ﹤0.01% 1099
2024
Q4 		$14.8K Buy
555
+511
+1,161% +$14.7K 0.01% 685
2024
Q3 		$1.03K Buy
+44
New +$999 ﹤0.01% 1020

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Aster Capital Management's AVBP Position: Q1 2026 in Review

Aster Capital Management sold out of ArriVent BioPharma (AVBP) in Q1 2026, closing a stake of 73 shares — an estimated $1.47K sold.

Aster Capital Management first reported a position in AVBP in Q3 2024 and held it in 5 quarters. The position peaked at $190K in Q2 2025. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • Aster Capital Management reported no remaining ArriVent BioPharma position as of Q1 2026 after selling out during the quarter.
  • Aster Capital Management sold 73 ArriVent BioPharma shares in Q1 2026, an estimated $1.47K.
  • Aster Capital Management first reported a position in ArriVent BioPharma in Q3 2024 and held it in 5 quarters.
  • Aster Capital Management's ArriVent BioPharma position peaked at $190K in Q2 2025.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on Aster Capital Management's 13F filing for Q1 2026, filed 13 May 2026.